From: Determinants of new drugs prescription in the Swiss healthcare market
Patient | Number of boxes prescribed | Drug | Active ingredient | Market | Physician | Canton |
---|---|---|---|---|---|---|
Patient A | 1 | Brand X 10 tablets 500 mg | N02BA01 | N02BA | Dr MD 001 | Aarau |
Patient A | 3 | Brand X 10 tablets 500 mg | N02BA01 | N02BA | Dr MD 002 | Bern |
Patient A | 1 | Brand X 20 tablets 500 mg | N02BA01 | N02BA | Dr MD 002 | Aarau |
Patient A | 1 | Brand X 10 supp 500 mg | N02BA01 | N02BA | Dr MD 002 | Bern |
Patient A | 4 | Brand X 10 tablets 500 mg | N02BA01 | N02BA | Dr MD 001 | Aarau |
Patient A | 1 | Brand Y 98 tablets 10 mg | C09AA02 | C09AA | Dr MD 001 | Aarau |
Patient A | 2 | Brand Y 28 tablets 10 mg | C09AA02 | C09AA | Dr MD 001 | Aarau |
Patient B | 3 | Brand Y 98 tablets 10 mg | C09AA02 | C09AA | Dr MD 007 | Vaud |
Patient B | 4 | Brand Z 20 tablets 500 mg | N02BA01 | N02BA | Dr MD 008 | Vaud |